Atreca, Inc. (BCEL)
Market Cap | 3.57M |
Revenue (ttm) | 263,000 |
Net Income (ttm) | -95.08M |
Shares Out | 39.65M |
EPS (ttm) | -2.43 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 122,115 |
Open | 0.0912 |
Previous Close | 0.0912 |
Day's Range | 0.0900 - 0.0931 |
52-Week Range | 0.0520 - 1.2000 |
Beta | 1.03 |
Analysts | Hold |
Price Target | 1.00 (+1,011.11%) |
Earnings Date | May 8, 2024 |
About BCEL
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozo... [Read more]
Financial Performance
In 2022, Atreca's revenue was $770,000, a decrease of -9.52% compared to the previous year's $851,000. Losses were -$90.53 million, -17.20% less than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BCEL stock is "Hold." The 12-month stock price forecast is $1.0, which is an increase of 1,011.11% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/4/n/press20-2208296.jpg)
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.'s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a colle...
![](https://cdn.snapi.dev/images/v1/i/r/press16-2207987.jpg)
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platfo...
![](https://cdn.snapi.dev/images/v1/g/m/press19-2207989.jpg)
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it ...
![](https://cdn.snapi.dev/images/v1/x/z/press1-2158118.jpg)
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
![](https://cdn.snapi.dev/images/v1/y/w/press7-2072506.jpg)
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...
![](https://cdn.snapi.dev/images/v1/b/a/press7-2018327.jpg)
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug...
![](https://cdn.snapi.dev/images/v1/k/j/press7-1920500.jpg)
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated
![](https://cdn.snapi.dev/images/v1/9/7/press1-1883437.jpg)
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...
![](https://cdn.snapi.dev/images/v1/y/v/press16-1856080.jpg)
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a ...
![](https://cdn.snapi.dev/images/v1/z/s/conf3-1835656.jpg)
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...
![](https://cdn.snapi.dev/images/v1/6/m/press18-1817848.jpg)
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression
![](https://cdn.snapi.dev/images/v1/s/d/conf4-1810708.jpg)
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and...
![](https://cdn.snapi.dev/images/v1/7/n/press4-1776631.jpg)
Atreca to Participate at Cowen's 43rd Annual Health Care Conference
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...
![](https://cdn.snapi.dev/images/v1/k/t/press19-1739789.jpg)
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics genera...
![](https://cdn.snapi.dev/images/v1/g/g/press12-1700390.jpg)
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
![](https://cdn.snapi.dev/images/v1/s/y/press17-1631579.jpg)
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on ...
![](https://cdn.snapi.dev/images/v1/3/v/conf15-1623508.jpg)
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
![](https://cdn.snapi.dev/images/v1/p/3/press12-1570945.jpg)
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
![](https://cdn.snapi.dev/images/v1/r/d/press16-1493920.jpg)
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
![](https://cdn.snapi.dev/images/v1/3/u/press12-1430412.jpg)
Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer
![](https://cdn.snapi.dev/images/v1/k/l/press18-1419829.jpg)
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
![](https://cdn.snapi.dev/images/v1/b/u/press13-1399170.jpg)
Atreca Announces Corporate Reorganization to Extend Cash Runway
Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets
![](https://cdn.snapi.dev/images/v1/m/j/press17-1368000.jpg)
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...
![](https://cdn.snapi.dev/images/v1/k/i/press6-1355042.jpg)
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”
SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...
![](https://cdn.snapi.dev/images/v1/j/9/conf6-1313786.jpg)
Atreca to Present at Upcoming Virtual Investor Conferences
SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...